bioRxiv ScienceSearch

Biology subjects

Barbosa, H.

Publications and source records attributed to Barbosa, H..

3 recordsLinked to original sources

Inpatient mobility to predict hospital-onset Clostridium difficile: a network approach

With hospital-onset Clostridium difficile Infection (CDI) still a common occurrence in the U.S., this paper examines the relationship between unit-wide CDI susceptibility and inpatient mobility and creates a predictive measure of CDI called \"Contagion Centrality\". A mobility network was constructed using two years of patient electronic health record (EHR) data within a 739-bed hospital (Jan. 2013 - Dec. 2014; n=72,636 admissions). Network centrality measures were calculated for each hospital unit (node) providing clinical context for each in terms of patient transfers between units (edges). Daily unit-wide CDI susceptibility scores were calculated using logistic regression and compared to network centrality measures to determine the relationship between unit CDI susceptibility and patient mobility. Closeness centrality was a statistically significant measure associated with unit susceptibility (p-value < 0.05), highlighting the importance of incoming patient mobility in CDI prevention at the unit-level. Contagion Centrality (CC) was calculated using incoming inpatient transfer rates, unit-wide susceptibility of CDI, and current hospital CDI infections. This measure is statistically significant (p-value <0.05) with our outcome of hospital-onset CDI cases, and captures the additional opportunities for transmission associated with inpatient transfers. We have used this analysis to create an easily interpretable and informative clinical tool showing this relationship and risk of hospital-onset CDI in real-time. Quantifying and visualizing the combination of inpatient transfers, unit-wide risk, and current infections help identify hospital units at risk of developing a CDI outbreak, and thus provide clinicians and infection prevention staff with advanced warning and specific location data to concentrate prevention efforts.

epidemiology

Precise tuning of gene expression output levels in mammalian cells

Precise, analogue regulation of gene expression is critical for development, homeostasis and regeneration in mammals. In contrast, widely employed experimental and therapeutic approaches such as knock-in/out strategies are more suitable for binary control of gene activity, while RNA interference (RNAi) can lead to pervasive off-target effects and unpredictable levels of repression. Here we report on a method for the precise control of gene expression levels in mammalian cells based on engineered, synthetic microRNA response elements (MREs). To develop this system, we established a high-throughput sequencing approach for measuring the efficacy of thousands of miR-17 MRE variants. This allowed us to create a library of microRNA silencing-mediated fine-tuners (miSFITs) of varying strength that can be employed to control the expression of user specified genes. To demonstrate the value of this technology, we used a panel of miSFITs to tune the expression of a peptide antigen in a mouse melanoma model. This analysis revealed that antigen expression level is a key determinant of the anti-tumour immune response in vitro and in vivo. miSFITs are a powerful tool for modulating gene expression output levels with applications in research and cellular engineering.

synthetic biology

Decoupling tRNA promoter and processing activities enables specific Pol-II Cas9 guide RNA expression

Spatial/temporal control of Cas9 guide RNA expression could considerably expand the utility of CRISPR-based technologies. Current approaches based on tRNA processing offer a promising strategy but suffer from high background. Here we developed a variant screening platform to identify differential sequence determinants of human tRNA promoter and processing activities. Rational design based on the ensuing principles allowed us to engineer an improved tRNA scaffold that enabled highly specific guide RNA production from a Pol-II promoter.

bioengineering